 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Outcome of Aflibercept-Bevacizumab Alternate Dosing in Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept |
| Daeun Shin, Jae Hui Kim |
|
J Korean Ophthalmol Soc. 2022;63(6):526-534. Published online June 15, 2022 DOI: https://doi.org/10.3341/jkos.2022.63.6.526 |
|
Outcome of Aflibercept-Bevacizumab Alternate Dosing in Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept Journal of the Korean Ophthalmological Society. 2022;63(6):526-534  Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration Clinical Ophthalmology. 2015;1315 Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye Clinical Ophthalmology. 2014;2129 Short-term Efficacy of Brolucizumab Injection for Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept Journal of Retina. 2021;6(2):145-149 <p>Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration</p> Clinical Ophthalmology. 2019;Volume 13:1289-1295 Comment on: ‘One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration’ Eye. 2017;32(2):477-479 Cost Utility Analysis Of Aflibercept, Ranibizumab, And Bevacizumab For The Treatment Of Neovascular Age-Related Macular Degeneration Value in Health. 2014;17(3):A287 Rapid response to intravitreal aflibercept in neovascular age-related macular degeneration after development of tachyphylaxis to bevacizumab and ranibizumab Taiwan Journal of Ophthalmology. 2014;4(1):40-44 Visual outcome following treatment with aflibercept in patients with neovascular age-related macular degeneration Acta Ophthalmologica. 2015;93:n/a-n/a Reply to: ‘Comment on: ‘One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration’ Eye. 2017;32(2):479-481 |
